|
|
|
|
|
|
|
|
|
|
CONCLUSIONSAmong patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer among those receiving niraparib than among those receiving placebo, regardless of the presence or absence
of gBRCA mutations or HRD status, with moderate bone marrow toxicity. (Funded
by Tesaro; ClinicalTrials.gov number, NCT01847274.)
0 comments :
Post a Comment
Your comments?
Note: Only a member of this blog may post a comment.